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Abstract
Classical cytotoxic therapy has been minimally useful in the treatment of hepatocellular carcinoma. In an effort to develop
a new approach to the treatment of this neoplasm, we have investigated the signal transduction pathways regulating the
growth of human hepatoma cells. In the data reported here, cyclic AMP (cAMP), a negative growth regulator for many cells
of epithelial origin, induced G1 synchronization and apoptosis in the HepG2 human hepatoma cell line. The effects of cAMP
on the components of the G1/S transition were analyzed. There was no detectable effect of two different cAMP analogs,
8-bromo cAMP or dibutyryl cAMP on the level of the D-type cyclins, cyclin E, cyclin-dependent kinase 2, cyclin-dependent
kinase 4, p53, or the cyclin-dependent kinase inhibitors p21 or p27. In contrast, the cAMP analogs induced a dramatic
downregulation of cyclin A protein, cyclin A messenger RNA, and cyclin A-dependent kinase activity. Cyclin A-dependent
kinase has been shown to be required for the G1^S transition. Furthermore, cyclin A deregulation has been implicated in the
pathogenesis of hepatocellular carcinoma. The data reported here suggest a novel signal transduction-based approach to
hepatoma therapy. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Primary hepatocellular carcinoma (HCC) is one of
the most common malignant tumors worldwide [1],
and HCC may be the most common fatal cancer [2].
In cases of localized HCC, surgical resection is po-
tentially curative. However, many patients with HCC
have metastatic disease at the time of initial diagno-
sis, and even in patients with HCC con¢ned to the
liver, curative surgical resection is frequently not an
option due to cirrhosis and other pathologic changes
in the liver parenchyma [3]. In patients with ad-
vanced disease, the average survival is 1 year or
less. Thus, the development of a new therapeutic
approach to HCC remains one of the most challeng-
ing areas in cancer research.
Uncontrolled proliferation is a universal property
of tumor cells. Recent studies in HCC using various
animal models, hepatoma cell lines, or primary hu-
man tumors have identi¢ed quantitative or qualita-
tive activation of growth-regulatory genes including
c-myc, ras, and cyclin A [4^8]. However, the func-
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tional roles of these gene products in HCC develop-
ment have yet to be de¢ned.
HCC is an intrinsically chemoresistant tumor [9].
Therefore, in an e¡ort to identify a new approach to
HCC treatment, we have examined the impact on
HCC growth of signal transduction pathway modu-
lators. In this study, we investigated the e¡ect of
cyclic AMP (cAMP) on cell cycle progression in
the human HepG2 hepatoma cell line. cAMP, which
acts as a second messenger for transmitting the sig-
nals of a diverse group of hormones and neurotrans-
mitters serves as either a positive or a negative
growth regulator, depending on the cell context
[10,11]. cAMP has been shown to induce G1 syn-
chronization, growth arrest, and terminal di¡erentia-
tion in certain cells [12^14]. The data presented here
demonstrate that cyclic AMP induces G1 synchroni-
zation and subsequent cell death in HepG2 cells.
Furthermore, examination of the components of
the G1^S phase transition in control and cAMP-
treated cells demonstrated that cAMP induces a se-
lective downregulation of cyclin A protein, downre-
gulation of cyclin A messenger RNA expression and
a selective block in the activity of cyclin A-dependent
kinase.
2. Materials and methods
2.1. Cells
The human hepatoma cell line HepG2 [5] was ob-
tained from the American Type Culture Collection
(ATCC) and cultured as a monolayer in RPMI 1640
medium with 10% heat-inactivated fetal bovine
serum, penicillin and streptomycin at 37‡C in 5%
CO2.
2.2. cAMP analogs and antibodies
8-Bromo-cAMP (8-br-cAMP, 8-bromo-adenosine-
3P :5P-monophosphate, cyclic monosodium salt) and
dibutyryl-cAMP (db-cAMP, N6,2P-O-dibutyryl-ad-
enosine-3P :5P-monophosphate, cyclic monosodium
salt) were obtained from Boehringer Mannheim.
Monoclonal anti-cyclin A antibody, polyclonal anti-
p27, -cdk2, -cdk4, -cyclin D1, -cyclin D2, and -cyclin
D3 antibodies were purchased from Santa Cruz Bio-
technology. Monoclonal anti-p21 antibody was pur-
chased from PharMingen. Monoclonal anti-p53 anti-
body was purchased from Oncogene Research
Products.
2.3. Cell cycle analysis
Exponentially growing cells were compared to cells
treated with 1 mM db-cAMP and 1 mM 8-br-cAMP
for 24, 48, and 72 h. Cells were harvested, ¢xed in
50% ethanol and incubated with RNAse A and the
DNA intercalating dye propidium iodide. Cell cycle
phase analysis was performed by £ow cytometry us-
ing a Becton Dickinson FACStar £ow cytometer and
Becton Dickinson Cell Fit software.
2.4. DAPI staining
Cells were washed two times with PBS and ¢xed
with 3.7% formaldehyde in PBS for 10 min at room
temperature. Fixed cells were washed two times with
PBS and 4,6-diamidino-2-phenylindole (DAPI, Sig-
ma) was added and allowed to incubate for 10 min
at room temperature. The cells were washed two
more times with PBS. Coverslips were mounted on
glass slides and analyzed by £uorescence microscopy
using a Zeiss Axiophot microscope.
2.5. Western blot analysis
Cell lysates were subjected to electrophoresis in
SDS-polyacrylamide gels. Western blot analysis was
performed as described previously [14]. Proteins were
detected using an enhanced chemiluminesence system
(ECL, Amersham).
2.6. Northern blot analysis
Total RNA was isolated from cells lysed in guani-
dium thiocyanate solution and Northern blot analy-
sis was performed as described previously [15] using
a 32P (ICN)-labeled 2.7-kb cyclin A cDNA probe
and 30 Wg total RNA per lane.
2.7. Immune complex kinase assay
The immune complex kinase assay was performed
as described previously [16]. Brie£y, cell lysates were
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Fig. 1. E¡ect of cAMP on cell cycle phase distribution in HepG2 cells. Exponentially growing cells and cells treated with 1 mM db-cAMP and


























incubated with primary antibody, immune complexes
were collected on protein A-Sepharose beads (Sig-
ma), the beads were washed extensively, resuspended
in kinase assay reaction mixture containing [Q-
32P]ATP (ICN) and histone H1 as substrate and in-
cubated for 30 min at 37‡C. The reaction was
stopped by adding 2USDS sample bu¡er and boil-
ing. Proteins were separated on 10% SDS-PAGE,
dried and autoradiographed using Kodak XAR-5
¢lm.
Fig. 2. cAMP analogs induce apoptosis in HepG2 cells. (A) Cells were treated with cAMP analogs for the times indicated. The per-
cent of apoptotic hypodiploid cells was determined by £ow cytometric analysis. (B) Cells were cultured in the absence (control) or
presence of either 1 mM 8-br-cAMP or 1 mM db-cAMP for 72 h. The cells were ¢xed with formaldehyde, stained with the nuclear
stain DAPI, and examined by £uorescence microscopy.
Fig. 3. Western blot analysis of D-type cyclins, cyclin E, cdk2, and cdk4 in control and cAMP-treated cells. Cells were cultured in the
absence (control) or presence of either 1 mM 8-br-cAMP or 1 mM db-cAMP for 72 h. Equal amounts of total protein (30 Wg) were
resolved by SDS-PAGE, transferred to nitrocellulose and probed with speci¢c antibodies. Proteins were detected by enhanced chemilu-
minescence.
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3. Results
3.1. cAMP induces cell cycle arrest
The cell cycle phase distribution of exponentially
growing HepG2 cells was compared to cells treated
with the cell-permeant cAMP analogs, db-cAMP and
8-bromo-cAMP (Fig. 1). Twenty-four hours after
cAMP addition there was a marked increase in the
percent of cells in G1. By 72 h following db-cAMP
and 8-br-cAMP addition, 76 and 79% of the HepG2
cells were arrested in G1, respectively. Growth curves
demonstrated that cells failed to grow in the presence
of cAMP, and that by 72 h of continuous exposure
the cells were dying, as evidenced by a decrease in the
viable cell count to below the initial number of cells
plated (data not shown). Untreated control cells, and
cells treated with either of two membrane-permeant
cAMP analogs were grown on coverslips, stained
with DAPI, and analyzed for changes in nuclear
morphology characteristic of apoptosis. In the cul-
tures treated with cAMP, there was an increase in
the percent of apoptotic cells, as detected by DNA
condensation and fragmentation in DAPI-stained
cells, and by the £ow cytometric detection of cells
with a hypodiploid DNA content (Fig. 2).
3.2. E¡ect of cAMP on G1 cyclins, cdk2 and cdk4
The ¢rst stages of the G1/S transition are regulated
by D-type cyclins which bind to cdk4 in mid-G1
prior to the restriction point, and by cyclin E which
binds and activates cdk2 later in G1 [17^19]. The
data in Fig. 1 demonstrated that cAMP induced
G1 phase-speci¢c arrest. Therefore, we examined
whether cAMP-induced growth arrest in HepG2 cells
was associated with decreased protein levels of the
D-type cyclins, cyclin E, cdk2, or cdk4. Western blot
analyses showed that cAMP had no detectable e¡ect
on the level of these proteins for up to 72 h of treat-
ment (Fig. 3).
3.3. Levels of cdk inhibitors, p21waf1=cip1 and p27kip1
after treatment with cAMP
Cdk inhibitors are critical regulators of cdk activ-
ity. It has been reported that cAMP can increase the
level of the cdk inhibitor p27Kip1 [20] and increase
binding of p27Kip1 with the cyclin^cdk2 complex.
Thus, cAMP-induced cell cycle arrest in HepG2 cells
might be mediated by upregulation of the cdk inhib-
itors p27Kip1 or p21Waf1=Cip1, and/or upregulation of
p53, a tumor suppressor protein that strongly trans-
activates the p21Waf1=Cip1 promoter [21]. As shown in
Fig. 4, cAMP had no detectable e¡ect on the level of
p53 or the cdk inhibitors, as determined by Western
blot analysis.
3.4. Downregulation of expression of cyclin A by
cAMP
Because there was no detectable change in the pro-
tein levels of the D-type cyclins, cyclin E, cdk2, cdk4,
p21Waf1=Cip1 or p27Kip1, we examined the protein level
Fig. 4. Levels of cyclin-dependent kinase inhibitors p21WAF1=CIP1 and p27KIP1, and p53 tumor suppressor protein after treatment with
cAMP analogs. (A) Cells were treated with 1 mM db-cAMP or 1 mM 8-br-cAMP for 72 h. (B) Cells were incubated with 1 mM
8-br-cAMP for the time indicated. Total cell lysates were subjected to Western blot analysis using anti-p21, -p27 and-p53 antibodies,
and detected by enhanced chemiluminescence.
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of cyclin A by Western blot analysis. Until recently
cyclin A was thought to function only in S phase and
in mitosis. Reznitsky and colleagues, however, dem-
onstrated that cyclin A can be rate-limiting for the
G1^S phase transition [22]. In marked contrast to
the other G1-regulatory components studied, the lev-
el of cyclin A protein was decreased after 24 h treat-
ment with cAMP, and cyclin A protein was almost
undetectable by 72 h following cAMP addition (Fig.
5).
3.5. Downregulation of cyclin A mRNA by cAMP
A principal mechanism of cAMP action is through
the regulation of gene expression. Therefore, we
tested if cAMP could downregulate cyclin A
mRNA. Kinetic analysis demonstrated progressive
loss of cyclin A mRNA in cAMP-treated cells. The
time course of mRNA downregulation corresponded
with the time-course of cyclin A protein downregu-
lation. These data are consistent with inhibition of
cyclin A transcription by cAMP (Fig. 5).
3.6. Inhibition of cyclin A^cdk2 associated kinase
activity
Because cyclin A/cdk2-associated kinase activity
can be essential to the late G1/S transition and S
phase progression, we examined whether decreased
expression of cyclin A was associated with an inhib-
ition of cdk2 activity. As shown in Fig. 6 cyclin A-
associated cdk2 activity was inhibited after incuba-
tion of HepG2 cells with cAMP. The protein levels
of p21 and cdk2 were not changed and thus the
block in cyclin A^cdk2 activity would appear to be
attributable to the cAMP-induced downregulation of
cyclin A.
4. Discussion
Cell cycle progression is regulated by the orches-
trated activation and inactivation of a family of cdks
[17,18,22,23]. Derangements in the cell cycle machi-
nery are pivotal to the uncontrolled cell growth char-
Fig. 6. Inhibition of cyclin A-associated and cdk2 kinase activity by cAMP. Cells were incubated with 1 mM 8-br-cAMP for the time
indicated. Cell lysates were prepared, immunoprecipitations were performed with either anti-cyclin A antibody or anti-cdk2 antibody,
and kinase activity was assayed using histone H1 (H1) as substrate.
Fig. 5. Down-regulation of cyclin A by cAMP. Untreated control cells were compared to cells treated with 1 mM 8-br-cAMP for the
time indicated. (A) Western blot analysis of cyclin A protein using monoclonal anti-cyclin A antibody and 60 Wg of protein per lane.
(B) Northern blot analysis. Total RNA was prepared, equal amounts (30 Wg) were loaded per lane, and Northern blot analysis was
performed using cDNA probes for cyclin A and for the control gene GAPDH [15].
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acteristic of malignant neoplasms [24]. In the data
presented here, elevation of intracellular cAMP
with hydrolysis-resistant cAMP analogs induced
growth arrest and apoptosis in human HCC cells.
Analysis of the impact of cAMP on HCC cell
cycle-regulatory proteins demonstrated that cAMP
induced speci¢c downregulation of cyclin A protein,
downregulation of cyclin A mRNA, and marked in-
hibition of cyclin A-dependent cdk2 activity.
Cyclin A forms a complex with cdc2 kinase in G2
and M phase, and with cdk2 kinase in S phase and in
G1. Cyclin A^cdk2 complexes participate in the con-
trol of DNA synthesis [25^27], and the abolition of
cyclin A function by microinjection of anti-cyclin A
antibody or by plasmids encoding cyclin A antisense
abrogates the synthesis of cellular DNA [28]. Dereg-
ulation and overexpression of cyclin A have been
linked to several forms of cancer, including HCC
[8,29,30]. In view of the fact that there is a clear
association between hepatitis B virus and HCC, it
is provocative that the cyclin A gene was originally
identi¢ed as the target of hepatitis B virus integration
in a human primary liver cancer, and that in that
tumor, cyclin A transcription was under the control
of the HBV promoter [31,32]. Consistent with a role
for cyclin A deregulation in HCC pathogenesis, an
analysis of patients with primary liver cancer demon-
strated that there was a very signi¢cant (P6 0.0001)
positive correlation between the cyclin A messenger
RNA level and the percentage of tumor cells in
S+G2/M [8]. In addition, a recent study of HCC
patients showed that when cyclin A was over-
expressed by the tumor cells, the median survival
was 6 months. In contrast, when cyclin A was not
overexpressed, the median survival was 29 months
[33].
In the experiments reported here, the loss of cyclin
A protein was accompanied by a loss of cyclin A
mRNA. These data suggest that cAMP may be act-
ing at the transcriptional level to block cyclin A syn-
thesis. This interpretation would be consistent with
previous studies showing cAMP-induced inhibition
of the cyclin A promoter [34,35]. However, similarly
to the e¡ect of cAMP on cell growth, this e¡ect is
context-speci¢c, because in other reports, cAMP has
been shown to stimulate the cyclin A promoter
[36,37].
A critical substrate of the cyclin A^cdk2 complex
is the transcription factor heterodimer E2F^DP,
which activates the promoter of genes required for
DNA synthesis [38,39]. It has been demonstrated
that phosphorylation of DP by cyclin A^cdk2 results
in release of the E2F^DP complex from its DNA
binding site [40]. Furthermore, when cyclin A^cdk2
catalyzed E2F^DP phosphorylation was blocked, the
cells died via apoptosis [40]. As demonstrated in the
data presented here, cAMP induced loss of cyclin A,
loss of cyclin A^cdk2 activity, and apoptosis. This
raises the possibility that a mechanism of apoptosis
in the cAMP-treated HCC cells may be loss of cyclin
A/cdk2-catalyzed phosphorylation of the E2F^DP
heterodimer.
In response to the inherent chemoresistance of
many of the most prevalent carcinomas of adult
life, including HCC, there has been a surge of inter-
est in signal transduction-based approaches to anti-
cancer therapy. A variety of approaches are being
developed to employ cAMP or cAMP-dependent
kinase (protein kinase A) as a therapeutic target.
Phosphodiesterase inhibitors, such as pentoxyphyl-
line, may be useful in combination therapy or in
chemoprevention protocols [41,42]. Protein kinase
A is found in distinct isoforms [43], and recent e¡orts
have been directed at developing site-selective ana-
logs and site-selective oligonucleotide antisense se-
quences that may have antiproliferative activity
[44^46]. The results presented here demonstrate that
cAMP induces G1 synchronization in HepG2 cells,
and that this growth arrest is associated with sup-
pression of cyclin A expression and function. These
data suggest that the cAMP/PKA pathway may be a
useful target in the development of new signal trans-
duction-based approaches to HCC chemoprevention
and therapy.
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